Cytokinetics, Incorporated (CYTK) — ESG & Values Scores

Environment story

Cytokinetics is a biopharmaceutical company with minimal direct operational environmental footprint, typical of clinical-stage and early-commercialization biotech firms. No disclosed Scope 1 or Scope 2 emissions data, net-zero target, or renewable energy commitments are evident in available filings. The company's environmental exposure derives primarily from contract manufacturing and research facility operations. Absence of climate commitments and emissions disclosure represents a material gap, though manufacturing outsourcing to third parties may partially mitigate direct accountability. No significant environmental controversies, toxic-waste liabilities, or water-resource disputes are documented in the 10-K.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Contract Manufacturing Outsourcing

Cytokinetics engages multiple third-party contract development manufacturing organizations (CDMOs) for manufacturing of aficamten, shifting operational emissions accountability to external partners.

Reduces direct operational carbon footprint but does not eliminate supply-chain emissions exposure.

Social story

Cytokinetics demonstrates moderate social governance maturity. The company has disclosed significant hiring and expansion of its sales force and executive staff in 2025 to support commercialization of MYQORZO, indicating active workforce development. However, critical diversity metrics, CEO-to-median-worker pay ratios, union standing, and detailed supply-chain labor audits are not disclosed in the 10-K. The company's research and development intensity (R&D expenses of $416 million in 2025) and employee-related costs ($171.5 million in 2025) reflect substantial investment in human capital. No documented labor disputes, NLRB complaints, or union-suppression activities are evident. Absence of explicit diversity reporting and supply-chain ethics disclosures represents a material governance gap for a commercial-stage biopharma firm.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Workforce Expansion for Commercialization

Cytokinetics hired a U.S. sales force and expanded executive and administrative staff primarily in Q4 2025 to support MYQORZO commercialization. General and administrative expenses increased 32% YoY to $284.3 million in 2025, reflecting commercial infrastructure buildout.

Demonstrates commitment to workforce development and employment creation for product commercialization.
Employee-Related Cost Investment

Internal employee-related R&D costs increased from $136.5 million (2024) to $171.5 million (2025), a 25.6% increase, reflecting hiring and retention efforts.

Suggests competitive compensation environment and investment in talent retention.

Governance story

Cytokinetics exhibits robust cybersecurity governance oversight with a structured Board Audit Committee framework, dedicated Chief Information Security Officer (Eric Brown, VP IT with 10+ years cybersecurity experience), and formalized incident-response protocols. The company demonstrates proactive cybersecurity risk management with regular Audit Committee briefings (minimum annually) and ongoing dialogue among CISO, CEO, and CFO. However, the 10-K does not disclose board independence percentage, share-class structure, annual lobbying expenditures, or active regulatory proceedings (antitrust, fraud, consumer-safety). The absence of dual-class voting language suggests single-class structure. No evidence of litigation, SEC consent decrees, or FTC/antitrust actions is presented. Governance documentation is comprehensive for IT risk but incomplete for traditional ESG governance metrics (board composition, political contributions, shareholder proposal history).

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Cybersecurity Risk Governance Framework

Board Audit Committee established as primary cybersecurity oversight body, composed of directors with expertise in risk management, technology, and finance. Annual cybersecurity posture reviews and strategic integration of cyber-risk into corporate objectives.

Formalized governance reduces material cybersecurity risk exposure and strengthens incident-response readiness.
Chief Information Security Officer Leadership

Eric Brown appointed as VP Information Technology and CISO with 10+ years cybersecurity experience and 20+ years IT background. Responsibilities include monitoring information systems, vulnerability identification, incident response, and escalation to executive management and Audit Committee.

Dedicated senior leadership ensures continuous monitoring and strategic response to cyber threats.
Incident Monitoring and Escalation Protocol

CISO maintains well-defined incident response plan with immediate mitigation actions and long-term remediation strategies. Significant cybersecurity matters escalated to Audit Committee for oversight and guidance.

Structured incident management reduces business continuity risk and enables rapid response.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Cytokinetics, Incorporated. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Cytokinetics, Incorporated in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)